share_log

Pfizer | DEFA14A: Others

Pfizer | DEFA14A: Others

辉瑞 | DEFA14A:其他
美股sec公告 ·  03/14 09:09
Moomoo AI 已提取核心信息
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule, according to a DEFA14A notice. The materials are related to the company's upcoming proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing, which is not preliminary and does not require a filing fee, indicates that Pfizer is preparing for matters related to its corporate governance that will be addressed in the proxy statement. This is a routine filing for the company and is part of the standard process of engaging with shareholders on governance issues.
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule, according to a DEFA14A notice. The materials are related to the company's upcoming proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing, which is not preliminary and does not require a filing fee, indicates that Pfizer is preparing for matters related to its corporate governance that will be addressed in the proxy statement. This is a routine filing for the company and is part of the standard process of engaging with shareholders on governance issues.
根据 DEFA14A 的通知,辉瑞公司已向美国证券交易委员会 (SEC) 提交了明确的额外材料,作为其委托声明时间表的一部分。这些材料与公司根据1934年《证券交易法》第14(a)条即将发布的委托书有关。该文件不是初步的,不需要缴纳申请费,表明辉瑞正在为委托书中将涉及的与公司治理有关的事项做准备。这是公司的例行申报,也是与股东就治理问题进行接触的标准流程的一部分。
根据 DEFA14A 的通知,辉瑞公司已向美国证券交易委员会 (SEC) 提交了明确的额外材料,作为其委托声明时间表的一部分。这些材料与公司根据1934年《证券交易法》第14(a)条即将发布的委托书有关。该文件不是初步的,不需要缴纳申请费,表明辉瑞正在为委托书中将涉及的与公司治理有关的事项做准备。这是公司的例行申报,也是与股东就治理问题进行接触的标准流程的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息